PMID: 3800703Dec 1, 1986Paper

Efficacy and safety of hemoglobin-polyethylene glycol conjugate (pyridoxalated polyethylene glycol hemoglobin) as an oxygen-carrying resuscitation fluid

Artificial Organs
K IwasakiT Uematsu


The safety and efficacy of a conjugate of pyridoxalated hemoglobin and polyethylene glycol (pyridoxalated PEG hemoglobin) were evaluated after administration to rats. The LD50 (lethal dose for 50% survival of group) of pyridoxalated polyethylene glycol (PEG) hemoglobin was greater than 200 ml/kg. Any pro- or anticoagulation activity was not demonstrated in in vitro coagulation tests. One day after 70% exchange-transfusion with pyridoxalated PEG hemoglobin, slight elevations of the serum glutamic-oxaloacetic transaminase, serum glutamic-pyruvic transaminase, and blood urea nitrogen values, which were 101.7 +/- 22.6 IU/L, 33.3 +/- 7.2 IU/L, and 23.1 +/- 1.4 mg/dl, respectively, were observed. However, these values were in the normal range after 3 days. With greater than 90% exchange-transfusion, all rats exchange-transfused with pyridoxalated PEG hemoglobin survived for greater than 2 weeks in contrast to the death of all the rats exchange-transfused with stroma-free hemoglobin or albumin.


Jan 1, 1978·Clinical Pharmacology and Therapeutics·J P SavitskyJ D Arnold
Dec 1, 1967·The Journal of Experimental Medicine·S F RabinerL H Friedman
Feb 1, 1984·Artificial Organs·T MitsunoK Yokoyama
Nov 1, 1984·Surgery, Gynecology & Obstetrics·H I FriedmanT J Nemeth
Nov 18, 1983·JAMA : the Journal of the American Medical Association·C Marwick
Dec 16, 1980·Biochemical and Biophysical Research Communications·K Ajisaka, Y Iwashita

❮ Previous
Next ❯


Jan 1, 1992·Biomaterials, Artificial Cells, and Immobilization Biotechnology : Official Journal of the International Society for Artificial Cells and Immobilization Biotechnology·H LiuK Ota
Nov 17, 2009·Methods in Enzymology·Hiromi SakaiEishun Tsuchida

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.